中国健康传媒集团有限公司

What 中国健康传媒集团有限公司 does

China Health Media Group Co., Ltd. (中国健康传媒集团有限公司) is a Beijing-headquartered central cultural enterprise established by the State Council on November 23, 2016 and operating under the supervision of the National Medical Products Administration (NMPA). The Ministry of Finance acts as the nominal investor and the group is classified as a state-owned enterprise, with no external equity financing. The group consolidates five wholly-owned subsidiaries — China Medical News (《中国医药报》社), China Medical Science and Technology Publishing House (中国医药科技出版社), Tianchuang Technology Information Technology Co., Ltd. (天创科技), Tianhe Exhibition Co., Ltd. (天和会展), and Tianxiang (Beijing) Health Technology Development Co., Ltd. (天享健康) — alongside the China Food and Drug Regulation Magazine and the China Food and Drug Website, functioning as the official propaganda mouthpiece and public opinion monitoring platform for China's drug regulatory system.

The group executes a 'Full Media, Big Data, Regulatory Think Tank' (全媒体、大数据、监管智库) three-pronged strategy across six business segments: integrated media (newspaper, magazine, website, mobile app, WeChat matrix with 10 official accounts), pharmaceutical and medical book publishing (including the 2025 edition Chinese Pharmacopoeia English version), public opinion big data (via Tianchuang's Public Opinion Monitoring Center, the food and drug public opinion monitoring system, and risk early warning platforms for health food and cosmetics), professional training and education (Tianxiang Health training platform and online pharmacist training platform established 2014), conferences and exhibitions (Smart Food and Drug Expo, National Traditional Chinese Medicine Scientific Supervision Conference), and the Health China Research Institute think tank (including rare disease policy research). Underlying technology integrates traditional publishing with digital platforms plus a proprietary 'Smoke Index' anomaly detection system that combines business registration, public opinion, regulatory, e-commerce, and enterprise operation data to compute enterprise-level risk scores.

Revenue is generated through six streams: subscription-based publishing (books, newspapers, magazine advertising), recurring public opinion monitoring and custom reports (weekly/monthly/quarterly/annual), professional services for training programs (e.g., 3,500 RMB per person for active medical device registration training), transaction-fee exhibitions and conferences, think tank research and consulting, and digital media advertising. The group's go-to-market is relationship-driven, anchored by its parent NMPA affiliation and extended through strategic cooperation agreements with provincial drug regulatory bureaus — including Beijing Changping District (March 2023), Shandong Province (November 2025), and Hubei Province (July 2026) — delivering institutional services to drug regulatory authorities, the food/drug/medical device/cosmetics industry, the general public, and research institutions across China.

Name

中国健康传媒集团有限公司

Legal name

中国健康传媒集团有限公司

Website

https://health-china.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

China Health Media Group is a Beijing-based state-owned central cultural enterprise under the National Medical Products Administration that operates as the official integrated media, public opinion monitoring, publishing, training, exhibition, and regulatory think tank platform for China's drug regulatory system, serving government regulators and the pharmaceutical industry nationwide.

Ownership category

akta.pro rank

Product category

Regulatory Media and Information Services

NAICS

Newspaper, Periodical, Book, and Directory Publishers (5131), Newspaper Publishers (51311)

SIC

Newspapers: Publishing Or Publishing & Printing (2711), Periodicals: Publishing Or Publishing & Printing (2721)

akta.pro primary industry

Government & Public Policy Publishing (Regulations, Gazettes, Legislative Tracking) (MPAJACAI)

akta.pro secondary industries

National & General-Interest Newspapers (Print & Digital) (MPAJADAA), News, Politics & Current Affairs Magazines (MPAJAEAO), Health Data, Vital Statistics & Population Health Informatics (BPAIAJAM)

Keywords

• Regulatory media services
• Drug supervision publishing
• Public opinion monitoring
• Health communication
• Food and drug news

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Publishing (Books, Newspapers, Magazines): Traditional publishing business including China Medical News newspaper, China Medical Science Press books, China Food and Drug Regulation magazine. Revenue from book sales, newspaper subscriptions, and advertising.
2. Public Opinion Monitoring Services: Fee-based public opinion monitoring and analysis services for government regulatory departments and industry enterprises. Weekly, monthly, quarterly and annual customized reports.
3. Training and Education: Professional training programs, seminars, and workshops for food and drug regulatory personnel and industry enterprises. Training fees for various programs.
4. Exhibitions and Conferences: Organizes exhibitions including the Smart Food and Drug Expo and National Traditional Chinese Medicine Scientific Supervision Conference. Event sponsorship and participation fees.
5. Think Tank and Research Services: Health China Research Institute conducts policy research and consulting services for regulatory authorities. Research projects and consulting fees.
6. Digital Media and Advertising: Online media platforms including China Food and Drug website, mobile apps, WeChat accounts, and Weibo for advertising and content monetization.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

China Health Media Group operates as the official media platform and public opinion stronghold for China's National Medical Products Administration (NMPA). It publishes newspapers, books, and magazines covering pharmaceutical, food, and medical device regulatory affairs, and operates the China Food and Drug Website, mobile apps, and WeChat media matrix. The group also runs public opinion monitoring and risk early warning platforms, professional training programs for regulatory personnel and industry enterprises, conferences and exhibitions, and a think tank for health policy research.

Product overview

China Health Media Group operates as a comprehensive media conglomerate with a 'Full Media, Big Data, Regulatory Think Tank' three-pronged strategy. The group consists of six business segments: integrated media (健康中国网, 中国食品药品网, 《中国医药报》), book publishing (中国医药科技出版社), public opinion big data (天创科技信息技术有限公司 with its 舆情监测中心, 舆情监测系统, 药品/保健食品/化妆品风险预警平台), training (天享健康 with 药师在线), exhibitions, and regulatory think tank (健康中国研究院). The group serves as the primary media platform for China's food and drug regulatory system, providing news, public opinion monitoring, risk early warning, training, and policy research services.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthy China Website (健康中国网) The group's official online portal serving as the primary hub for health news, regulatory information, and corporate announcements distributed to regulators, industry, and the public.
• China Food and Drug Website (中国食品药品网) Major online media platform providing comprehensive news coverage on food, drug, medical device, and cosmetics regulatory developments for industry professionals.
• China Medical News (《中国医药报》) National newspaper supervised by NMPA delivering authoritative pharmaceutical industry news and regulatory policy coverage to regulators, manufacturers, and medical institutions.
• China Medical Science and Technology Publishing House (中国医药科技出版社) Publishing house producing medical and pharmaceutical books, educational materials, and digital textbook platforms for health professionals and students.
• China Food and Drug Regulation Magazine (《中国食品药品监管》杂志) Academic journal covering food and drug regulatory science, providing in-depth analysis and academic exchange for regulatory professionals and researchers.
• Public Opinion Monitoring Center (舆情监测中心)
• China Health Food Risk Early Warning Platform (中国保健食品风险预警平台) Risk early warning platform that integrates multi-source data to build industry-specific risk models and enterprise risk indices for the health food industry.
• China Cosmetics Risk Early Warning Platform (中国化妆品风险预警平台) Data-driven risk warning platform for the cosmetics sector that calculates enterprise risk scores using regulatory, public opinion, and operational data models.
• Pharmacist Online (药师在线) Online training platform established in 2014 providing national pharmacist qualification examination education and continuing professional training for licensed pharmacists.
• Shishi Yaowen Mobile App (食事药闻APP) Mobile application providing integrated food and drug safety news and regulatory information to general consumers and industry professionals.
• Tianxiang Health Training Platform (天享健康) High-end training platform under Tianxiang (Beijing) Health Technology Development that delivers in-person and online professional training programs for food and drug regulatory authorities and industry enterprises.
• Public Opinion Weekly Report (《舆情周刊》) Weekly public opinion report analyzing food, drug, medical device, and cosmetics safety hotspots, delivered to leaders at national market regulation and NMPA bureaus.
• Health China Research Institute (健康中国研究院)

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Hubei Provincial Medical Products Administration (湖北省药监局)coreStrategic or Co-development Partner · 9 July 2026Strategic cooperation framework agreement signed on July 9, 2026 to deepen cooperation in regulatory science, news publicity, public opinion management, and research topics. The collaboration will establish closer strategic partnerships in areas including comprehensive media platform communication, science popularization, legal publicity, health big data, online and offline training, industrial development events, and academic exchange.
• Shandong Provincial Medical Products Administration (山东省药监局)coreStrategic or Co-development Partner · 19 November 2025Strategic cooperation agreement signed on November 19, 2025 for deepened cooperation in news publicity, public opinion monitoring, and training exchange. Both parties will establish closer strategic partnerships in areas including news publicity, book publishing, public opinion monitoring and early warning, and regulatory science research to improve drug regulatory efficiency and support high-quality development of the pharmaceutical industry.
• Beijing Changping District People's Government (北京市昌平区人民政府)coreStrategic or Co-development Partner · 3 March 2023Strategic cooperation agreement signed on March 3, 2023 during the 'Meeting at Life Valley, Fighting for a Strong Start' signing event. The partnership focuses on integrated media platform communication and industry-academia-research collaboration to promote the high-quality development of the biopharmaceutical industry in Changping District. The group will leverage its comprehensive media platform to enhance the influence and clustering effect of Changping's 'Two Valleys and One Park' biopharmaceutical industry.
• Beijing Normal University and Renmin University (北京师范大学、中国人民大学)minorStrategic or Co-development PartnerCollaborative research partnerships with top universities for public opinion data analysis and food/drug regulatory communication research. The group collaborates with these institutions for public opinion data analysis and academic research on food and drug regulatory communication.
• Provincial and Municipal Regulatory Bureaus (省级及地方政府)coreStrategic or Co-development PartnerStrategic cooperation partnerships with multiple provincial regulatory bureaus and local governments across China for regulatory publicity and public welfare projects. The group has established strategic cooperation relationships with multiple provincial bureaus and local governments.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Wolters Kluwer Health: A global provider of professional health information, drug data, and clinical decision support serving regulators and pharmaceutical enterprises; comparable as an established international incumbent in regulatory and scientific health information publishing that the group's big data platforms may compete with in cross-border contexts.
• 新华社 (Xinhua News Agency): China's official state news agency operating the world's largest news-gathering network; comparable as a central state-owned media institution with diversified publishing, digital, and data services backed by government mandate.
• 人民日报社 (People's Daily): The official newspaper of the CPC Central Committee and the largest state-owned media group in China; comparable as the broader incumbent in the central state-owned media landscape that operates newspaper, digital, and publishing businesses under government direction.
• 南方报业传媒集团 (Southern Media Group): One of China's largest provincial-level state-controlled media conglomerates operating newspapers, magazines, digital platforms, and publishing houses; comparable as a multi-format state-owned media group with diversified revenue streams.
• 中国新闻社 (China News Service): A central state-owned news organization focused on domestic and overseas Chinese affairs coverage; comparable as a central SOE media outlet with multi-channel publishing operations.

Direct peers

• 中国中医药报社 (China TCM News): The official newspaper of the National Administration of Traditional Chinese Medicine, directly comparable as a sector-specific state media outlet that combines newspaper publishing, policy communication, and digital media for a Chinese health regulator.
• 健康报社 (Health News): The official newspaper under the National Health Commission, directly comparable as another central state-owned health-focused media organization producing authoritative health news and policy communication for a top-tier Chinese health regulator.
• 中国卫生杂志社 (China Health Journal): An authoritative academic journal covering health policy and administration, comparable as a state-affiliated health policy publication serving regulatory and academic audiences.

Emerging players

• 丁香园 (DXY): A leading private-sector digital health professional platform serving clinicians and the pharmaceutical industry with content, community, and continuing education; comparable as an emerging player in healthcare professional media and B2B pharma information services, competing for the same enterprise training and information budgets.
• 医脉通 (Yimaitong): A private online platform providing clinical decision support, pharmaceutical information, and continuing medical education to Chinese healthcare professionals; comparable as an emerging digital health information and e-learning company overlapping with the group's training and information services.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E4%B8%AD%E5%9B%BD%E5%81%A5%E5%BA%B7%E4%BC%A0%E5%AA%92%E9%9B%86%E5%9B%A2%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 中国健康传媒集团有限公司